Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 5/2005

01-05-2005 | Regular Paper

Changes in hippocampal GABABR1 subunit expression in Alzheimer’s patients: association with Braak staging

Authors: Masahiko Iwakiri, Katsuyoshi Mizukami, Milos D. Ikonomovic, Masanori Ishikawa, Shin Hidaka, Eric E. Abrahamson, Steven T. DeKosky, Takashi Asada

Published in: Acta Neuropathologica | Issue 5/2005

Login to get access

Abstract

Alterations in the γ-aminobutyric acid (GABA) neurotransmitter and receptor systems may contribute to vulnerability of hippocampal pyramidal neurons in Alzheimer’s disease (AD). The present study examined the immunohistochemical localization and distribution of GABAB receptor R1 protein (GBR1) in the hippocampus of 16 aged subjects with a range of neurofibrillary tangle (NFT) pathology as defined by Braak staging (I–VI). GBR1 immunoreactivity (IR) was localized to the soma and processes of hippocampal pyramidal cells and some non-pyramidal interneurons. In control subjects (Braak I/II), the intensity of neuronal GBR1 immunostaining differed among hippocampal fields, being most prominent in the CA4 and CA3/2 fields, moderate in the CA1 field, and very light in the dentate gyrus. AD cases with moderate NFT pathology (Braak III/IV) were characterized by increased GBR1-IR, particularly in the CA4 and CA3/2 fields. In the CA1 field of the majority of AD cases, the numbers of GBR1-IR neurons were significantly reduced, despite the presence of Nissl-labeled neurons in this region. These data indicate that GBR1 expression changes with the progression of NFT in AD hippocampus. At the onset of hippocampal pathology, increased or stable expression of GBR1 could contribute to neuronal resistance to the disease process. Advanced hippocampal pathology appears to be associated with decreased neuronal GBR1 staining in the CA1 region, which precedes neuronal cell death. Thus, changes in hippocampal GBR1 may reflect alterations in the balance between excitatory and inhibitory neurotransmitter systems, which likely contributes to dysfunction of hippocampal circuitry in AD.
Literature
1.
Amaral DG, Insausti R (1990) Hippocampal formation. In: Paxinos G (ed) The human nervous system. Academic Press, New York, pp 711–756
2.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, D.C.
3.
Armstrong DM, Ikonomovic MD, Sheffield R, Wenthold RJ (1994) AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer’s disease. Brain Res 639:207–216
4.
Armstrong DM, Ikonomovic MD, Mizukami K, Mishizin A, Sheffield R, Wolfe BB (1998) Glutamatergic mechanisms in Alzheimer’s disease. Advances in Neurodegenerative Disorder: In Marwah J, Teitelbaum H (eds) Alzheimer’s and Aging, vol 2, Prominent Press, Scottsdale, pp 71–97
5.
Billinton A, Ige AO, Wise A, White JH, Disney GH, Marshall FH, Waldvogel HJ, Faull RLM, Emson PC (2000) GABAB receptor heterodimer-component localization in human brain. Mol Brain Res 77:111–124
6.
Bonard LS (1995) N-Methyl-d-aspartate transmission modulates GABAB-mediated inhibition of rat hippocampal pyramidal neurons in vitro. Neuroscience 68:637–643
7.
Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMed
8.
Chu DC, Penney JB Jr, Young AB (1987) Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer’s disease. Neurosci Lett 82:246–252
9.
Chu DCM, Penny JB, Young AB (1987) Cortical GABAB and GABAA receptors in Alzheimer’s disease: a quantitative autoradiographic study. Neurology 37:1454–1459
10.
Duvernoy HM (1998) The human hippocampus, 2nd edn. Springer, Berlin
11.
Flood DG, Guarnaccia M, Coleman PD (1987) Dendritic extent in human CA2–3 hippocampal pyramidal neurons in normal aging and senile dementia. Brain Res 409:88–96
12.
Hof PR (1996) Morphology and neurochemical characterics of the vulnerable neurons in brain aging and Alzheimer’s disease. Eur Neurol 37:71–81
13.
Ikonomovic DM, Mizukami K, Davies P, Hamilton RL, Sheffield R, Armstrong DM (1997) The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol 56:1018–1027
14.
Ikonomovic MD, Mizukami K, Warde D, Sheffield R, Hamilton R, Wenthold RJ, Armstrong DM (1999) Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer’s disease. Exp Neurol 160:194–204
15.
Ikonomovic MD, Nocera R, Mizukami K, Armstrong DM (2000) Age-related loss of the AMPA receptor subunits GluR2/3 in the human nucleus basalis of Meynert. Exp Neurol 166:363–375
16.
Jicha GA, Bozer R, Kazam IG, Davies P (1997) Alz-50 and MC1, a new monoclonal antibody raised to paired helical filaments, recognize confirmational epitopes on recombinant tau. J Neurosci Res 48:128–132
17.
Jones KA, borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ, Johnson M, Gunwaldsen C, huang LY, Tang C, Shen Q, Salon JA, Morse K, Laz T, Smith KE, Nagarathnam D, Noble SA, Branchek TA, Gerald C (1998) GABAB receptors function as a heterometric assembly of the subunits GABABR1 and GABABR2. Nature 396:674–679CrossRefPubMed
18.
Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, mosbacher J, bichoff S, Kulik A, Shigemoto R, Karschin A, Bettler B (1998) GABAB-receptor subtypes assemble into functional heterometric complexs. Nature 396:683–687CrossRefPubMed
19.
Luscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA (1997) G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19:687–695CrossRefPubMed
20.
Macdonald RL, Olsen RW (1994) GABAA receptor channels. Annu Rev Neurosci17:569–602
21.
McKhann G, Drachman D, Folstein M, Katzman, R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMed
22.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMed
23.
Mize RR (1994) Quantitative image analysis for immunocytochemistry and in situ hybridization. J Neurosci Methods 54:219–237
24.
Mizukami K, Ikonomovic MD, Grayson DR, Rubin RT, Warde D, Sheffield R, Hamilton RL, Davies P, Armstrong DM (1997) Immunohistochemical study of GABAA receptor β2/3 subunits in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes. Exp Neurol 147:333–345
25.
Mizukami K, Grayson DR, Ikonomovic MD, Sheffield R, Armstrong DM (1998) GABAA receptor β2 and β3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimer-related neuropathology. Mol Brain Res 56:268–272
26.
Mizukami K, Ikonomovic MD, Grayson DR, Sheffield R, Armstrong DM (1998) Immunohistochemical study of GABAA receptor α1 subunit in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes. Brain Res 799:148–155
27.
Mizukami K, Sasaki M, Ishikawa M, Iwakiri M, Hidaka S, Shiraishi H, Iritani S (2000) Immunohistochemical localization of GABAB receptor in the hippocampus of subjects with schizophrenia. Neurosci Lett 283:101–104
28.
Mizukami K, Ishikawa M, Hidaka S, Iwakiri M, Sasaki M, Iritani S (2002) Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatry 26:393–396CrossRef
29.
Möhler H, Benke D, Benson J, Lüscher B, Rudolph U, Fritschy JM (1997) Diversity in structure, pharmacology, and regulation of GABAA receptors. In: Enna SJ, Bowery NG (eds) GABA receptors, 2nd edn. Humana Press, Clifton, pp 11–36
30.
Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer’s disease cholinergic or glutamatergic? FASEB J 4:2745–2752
31.
Pfrieger FW, Gottmann K, Lux HD (1994) Kinetics of GABAB receptor-mediated inhibition of calcium currents and excitatory synaptic transmission in hippocampal neurons in vitro. Neuron 12:97–107
32.
Premkumar LS, Gage PW (1994) Potassium channels activated by GABAB agonists and serotonin in cultured hippocampal neurons. J Neurophysiol 71: 2570–2575
33.
Rössler M, Zarski R, Bohl J, Ohm TG (2002) Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer’s disease. Acta Neuropathol 103:363–369
34.
Smolen AJ (1990) Image analytic techniques for quantification of immunohistochemical staining in the nervous system. In: Conn PM (ed) Methods in Neurosciences, vol 3. Academic Press, New York, pp 208–229
35.
West MJ (1993). Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 14:287–293
36.
White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, Marshall FH (1998) Heterodimerization is required for the formation of a functional GABAB receptor. Nature 396:679–682CrossRefPubMed
37.
Wu LG, Saggau P (1995) GABAB receptor-mediated presynaptic inhibition in guinea-pig hippocampus is caused by reduction of presynaptic Ca2+ influx. J Physiol 485:649–657
38.
Yung KKL, Ng TKY, Wong CKC (1999) Subpopulations of neurons in the rat neotriatum display GABABR1 receptor immunoreactivity. Brain Res 830:345–352
Metadata
Title
Changes in hippocampal GABABR1 subunit expression in Alzheimer’s patients: association with Braak staging
Authors
Masahiko Iwakiri
Katsuyoshi Mizukami
Milos D. Ikonomovic
Masanori Ishikawa
Shin Hidaka
Eric E. Abrahamson
Steven T. DeKosky
Takashi Asada
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 5/2005
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-005-0985-9

Other articles of this Issue 5/2005

Acta Neuropathologica 5/2005 Go to the issue

Short Original Communication

No prognostic impact of survivin expression in glioblastoma

Regular Paper

Klotho insufficiency causes decrease of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal anterior horn cells

Regular Paper

Stereological studies of capillary length density in the frontal cortex of schizophrenics

Regular Paper

Silver staining profiles distinguish Pick bodies from neurofibrillary tangles of Alzheimer type: comparison between Gallyas and Campbell-Switzer methods

Regular Paper

Aberrant neuronal-glial differentiation in Taylor-type focal cortical dysplasia (type IIA/B)

Regular Paper

Thrombus and encapsulated hematoma in cerebral cavernous malformations